Cara Therapeutics Inc (CARA)

0.271 -0.03 (-11.00%) USD  |  NASDAQ  |  Jun 28, 16:00
0.271 0.00 (0.00%) After-Hours: 20:00
More

Cara Therapeutics Research and Development Expense (TTM): 106.14M for March 31, 2024

Research and Development Expense (TTM) Chart

Historical Research and Development Expense (TTM) Data

View and export this data back to 2013. Upgrade now.
Date Value
March 31, 2024 106.14M
December 31, 2023 108.51M
September 30, 2023 106.10M
June 30, 2023 105.34M
March 31, 2023 94.94M
December 31, 2022 91.88M
September 30, 2022 88.70M
June 30, 2022 79.52M
March 31, 2022 84.84M
December 31, 2021 82.70M
September 30, 2021 87.01M
June 30, 2021 92.56M
March 31, 2021 93.45M
December 31, 2020 107.85M
September 30, 2020 110.58M
June 30, 2020 125.50M
March 31, 2020 123.75M
December 31, 2019 113.82M
September 30, 2019 106.76M
June 30, 2019 93.07M
March 31, 2019 85.71M
December 31, 2018 75.53M
Date Value
September 30, 2018 64.31M
June 30, 2018 51.16M
March 31, 2018 41.12M
December 31, 2017 48.52M
September 30, 2017 57.22M
June 30, 2017 57.74M
March 31, 2017 61.54M
December 31, 2016 49.25M
September 30, 2016 36.54M
June 30, 2016 32.46M
March 31, 2016 26.38M
December 31, 2015 21.22M
September 30, 2015 17.11M
June 30, 2015 17.74M
March 31, 2015 16.25M
December 31, 2014 15.07M
September 30, 2014 13.59M
June 30, 2014 11.14M
March 31, 2014 9.964M
December 31, 2013 8.685M
September 30, 2013 7.73M

R&D Expense Definition

R&D expense is a line item from many companies' income statements.

Read full definition.

Research and Development Expense (TTM) Range, Past 5 Years

79.52M
Minimum
Jun 2022
125.50M
Maximum
Jun 2020
100.52M
Average
105.34M
Median
Jun 2023

Research and Development Expense (TTM) Benchmarks

Nektar Therapeutics 111.10M
Stereotaxis Inc 9.77M
Verastem Inc 67.05M
PTC Therapeutics Inc 587.57M
Ocugen Inc 36.84M